Stockreport

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF — Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway — — Prior Phase 2a [Read more]